宫瘤消胶囊对子宫内膜异位症气滞血瘀证血管生成机制的影响

发布时间：2018-04-16 23:37

本文选题：子宫内膜异位症 + 气滞血瘀证　；参考：《中国实验方剂学杂志》2017年21期

【摘要】：目的:探讨宫瘤消胶囊治疗子宫内膜异位症(EMs)气滞血瘀证的临床疗效及对血管内皮生长因子(VEGF),基质金属蛋白酶(MMP),碱性成纤维细胞生长因子(b FGF),转化生长因子-β1(TGF-β1)和肿瘤坏死因子-α(TNF-α)等促血管生成因子水平的影响。方法:将128符合EMs气滞血瘀证患者,采用SAS软件生成的,随机按数字表法分为对照组和观察组各64例。两组患者均服用孕三烯酮胶囊,2.5 mg/次,2次/周,于月经第1天开始,每周固定时间服药。观察组加服宫瘤消胶囊,4粒/次,3次/d。两组疗程均连续治疗6个月经周期。经期疼痛情况采用视觉模拟评分(VAS)评分,进行治疗前后非月经期的盆腔痛、性交疼痛、盆腔压痛、骶韧带触痛结节和气滞血瘀证评分;检测治疗前后血清癌抗原125(CA125),CA199,VEGF,MMP-2,MMP-9,b FGF,TGF-β1和TNF-α水平。结果:观察组临床总有效率为91.67%,高于对照组的76.27%(χ2=5.255,P0.05);观察组在第4,5,6个月经周期VAS评分均低于对照组(P0.01);治疗后观察组非月经期的盆腔痛、性交疼痛、盆腔压痛、骶韧带触痛结节评分均低于对照组(P0.01),观察组气滞血瘀证评分低于对照组(P0.01);观察组患者血清CA125和CA199水平均低于对照组(P0.01);观察组患者血清VEGF,MMP-2,MMP-9,b FGF,TGF-β1和TNF-α水平均低于对照组(P0.01)。结论:宫瘤消胶囊治疗子宫内膜异位症气滞血瘀证患者,能显著缓解患者的疼痛相关症状,提高临床疗效,并能降低VEGF等促血管生成因子水平,从不同靶点抑制新生血管的形成,起到控制病情的作用。
[Abstract]:Objective: to investigate the clinical effect of Gongliuxiao capsule in treating endometriosis with syndrome of Qi stagnation and blood stasis, and to investigate the effects of Gongliuxiao capsule on vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMPP), basic fibroblast growth factor (bFGF), transforming growth factor- 尾 _ (1) (TGF- 尾 _ (1)) and TGF- 尾 _ (1) in endometriosis.Effect of tumor necrosis factor-伪 and TNF- 伪 on the level of angiogenic factors.Methods: the patients with EMs Qi stagnation and Blood stasis Syndrome were randomly divided into control group (n = 64) and observation group (n = 64).The patients in both groups were treated with pregnancy trienone capsule 2. 5 mg/ twice a week, starting on the first day of menstruation and taking medicine at a fixed time every week.The observation group was treated with 4 capsules of Gongliuxiao capsule / 3 times per day.The two groups were treated continuously for 6 menstrual cycles.Visual analogue scale (VASS) was used to evaluate the pain in menstrual period, including pelvic pain, sexual pain, pelvic tenderness, tenderness of sacral ligament and blood stasis of qi before and after treatment, and the levels of serum cancer antigen 125 CA125 / CA199VEGFU MMP-2MMP-9b FGFTGF- 尾 1 and TNF- 伪 were detected before and after treatment.Results: the total clinical effective rate of the observation group was 91.67, which was higher than that of the control group (76.27), the VAS score of the observation group was lower than that of the control group in the 4th week (P 0.05), 6 menstrual cycles in the observation group was lower than that in the control group (P 0.01), after treatment, the pelvic pain, sexual intercourse pain and pelvic tenderness in the observation group were lower than those in the control group.The score of the sacral ligament tenderness nodule was lower than that of the control group (P 0.01), the score of qi stagnation and blood stasis in the observation group was lower than that of the control group (P 0.01), the levels of serum CA125 and CA199 in the observation group were lower than those in the control group (P 0.01), and the serum levels of VEGF, MMP-2, MMP-9, FGF- 尾 1 and TNF- 伪 in the observation group were lower than those in the control group (P 0.01).Conclusion: Gongyuxiao capsule in treating endometriosis patients with Qi stagnation and blood stasis syndrome can significantly relieve the pain related symptoms, improve the clinical efficacy, and reduce the level of angiogenic factors such as VEGF.From different targets inhibit the formation of neovascularization, play a role in controlling the disease.
【作者单位】：郑州大学第一附属医院;
【基金】：河南省医药科技攻关项目(2016020103)
【分类号】：R271.9

【相似文献】